SG10201506873WA - Fast-dissolve dosage forms of 5-ht2c agonists - Google Patents

Fast-dissolve dosage forms of 5-ht2c agonists

Info

Publication number
SG10201506873WA
SG10201506873WA SG10201506873WA SG10201506873WA SG10201506873WA SG 10201506873W A SG10201506873W A SG 10201506873WA SG 10201506873W A SG10201506873W A SG 10201506873WA SG 10201506873W A SG10201506873W A SG 10201506873WA SG 10201506873W A SG10201506873W A SG 10201506873WA
Authority
SG
Singapore
Prior art keywords
fast
dosage forms
ht2c agonists
dissolve dosage
dissolve
Prior art date
Application number
SG10201506873WA
Other languages
English (en)
Inventor
Anthony C Blackburn
Scott Stirn
Yun Shan
Anna Shifrina
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of SG10201506873WA publication Critical patent/SG10201506873WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10201506873WA 2010-09-01 2011-08-31 Fast-dissolve dosage forms of 5-ht2c agonists SG10201506873WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40258910P 2010-09-01 2010-09-01

Publications (1)

Publication Number Publication Date
SG10201506873WA true SG10201506873WA (en) 2015-10-29

Family

ID=44645827

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201506873WA SG10201506873WA (en) 2010-09-01 2011-08-31 Fast-dissolve dosage forms of 5-ht2c agonists
SG2013015607A SG188363A1 (en) 2010-09-01 2011-08-31 Fast-dissolve dosage forms of 5-ht2c agonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013015607A SG188363A1 (en) 2010-09-01 2011-08-31 Fast-dissolve dosage forms of 5-ht2c agonists

Country Status (11)

Country Link
US (1) US20140148442A1 (https=)
EP (1) EP2611781A1 (https=)
JP (1) JP2013536858A (https=)
KR (1) KR20130138768A (https=)
CN (1) CN103189358A (https=)
AU (1) AU2011296027A1 (https=)
CA (1) CA2808900A1 (https=)
IN (1) IN2013DN02552A (https=)
MX (1) MX2013002430A (https=)
SG (2) SG10201506873WA (https=)
WO (1) WO2012030951A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013536859A (ja) 2010-09-01 2013-09-26 アリーナ ファーマシューティカルズ, インコーポレイテッド 5−ht2cアゴニストの非吸湿性塩
KR20130138770A (ko) 2010-09-01 2013-12-19 아레나 파마슈티칼스, 인크. 광학적으로 활성 산을 갖는 로르카세린의 염
AU2011296015B2 (en) 2010-09-01 2015-11-12 Arena Pharmaceuticals, Inc. Administration of lorcaserin to individuals with renal impairment
JP6272695B2 (ja) 2010-09-01 2018-01-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 体重管理のために有用な5−ht2cアゴニストの改変放出剤形
JP2015534563A (ja) 2012-10-09 2015-12-03 アリーナ ファーマシューティカルズ, インコーポレイテッド 体重管理の方法
WO2014135545A1 (en) * 2013-03-05 2014-09-12 Sandoz Ag Solid dispersion comprising amorphous lorcaserin hydrochloride
EP2999692A1 (en) * 2013-05-20 2016-03-30 LEK Pharmaceuticals d.d. Novel synthetic processes to 8-chloro-3-benzo[d]azepine via friedel-crafts alkylation of olefin
EP2868656A1 (en) * 2013-11-05 2015-05-06 LEK Pharmaceuticals d.d. Stabilized amorphous lorcaserin hydrochloride
WO2015096119A1 (zh) * 2013-12-27 2015-07-02 杭州普晒医药科技有限公司 氯卡色林盐及其晶体、其制备方法和用途
US9981912B2 (en) 2014-04-21 2018-05-29 Hangzhou Pushai Pharmaceutical Technology Co., Ltd. Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof
CN103901151A (zh) * 2014-04-23 2014-07-02 湖北朗昕生化药业有限公司 一种hplc法检测氯卡色林盐酸盐含量的方法
TW201618787A (zh) 2014-10-30 2016-06-01 艾尼納製藥公司 組合物及方法
WO2018000094A1 (en) 2016-06-29 2018-01-04 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2561916B1 (fr) 1984-03-30 1987-12-11 Lafon Labor Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US5073374A (en) 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
US5219574A (en) 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5188825A (en) 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
WO1993000094A2 (en) * 1991-06-21 1993-01-07 Smithkline Beecham Plc Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
ATE216577T1 (de) 1992-01-29 2002-05-15 Takeda Chemical Industries Ltd Schnellösliche tablette und ihre herstellung
DE4203932A1 (de) 1992-02-11 1993-08-12 Deutsche Aerospace Sende-/empfangsmodul
US5503846A (en) 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
ATE208615T1 (de) 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5851553A (en) 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5595761A (en) 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5635210A (en) 1994-02-03 1997-06-03 The Board Of Regents Of The University Of Oklahoma Method of making a rapidly dissolving tablet
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
GB9421836D0 (en) 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US5807577A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5807578A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
JP2000508339A (ja) 1996-10-01 2000-07-04 シーマ・ラブス・インコーポレイテッド 味隠蔽マイクロカプセル組成物及び製造方法
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
GB0111186D0 (en) * 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
US20030119060A1 (en) * 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
WO2003086303A2 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
PL2332921T3 (pl) 2003-06-17 2016-08-31 Arena Pharm Inc Chlorowodorek 8-chloro-1-metylo-2,3,4,5-tetrahydro-1H-3-benzazepiny
CN1805938B (zh) * 2003-06-17 2010-06-16 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
TW200510324A (en) * 2003-08-11 2005-03-16 Lilly Co Eli 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
US20080009478A1 (en) * 2003-10-22 2008-01-10 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases
SI1720836T1 (sl) * 2004-02-25 2014-06-30 Eli Lilly And Company 6-substituirani 2,3,4,5-tetrahidro-1h-benzo (d)azepini kot agonisti 5-ht2c receptorja
NZ555981A (en) * 2004-12-21 2011-01-28 Arena Pharm Inc Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
BRPI0515862A2 (pt) * 2004-12-23 2011-10-11 Arena Pharm Inc uso de fentermina e agonista seletivo do receptor de 5ht-2c na preparação de composições, composições moduladoras do receptor de 5ht-2c e forma de dosagem unitária compreendendo as mesmas
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
CN101253153A (zh) * 2005-09-01 2008-08-27 伊莱利利公司 作为5-HT<sub>2c</sub>受体激动剂的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂䓬
ATE438627T1 (de) * 2005-09-01 2009-08-15 Lilly Co Eli 6-substituierte- 2,3,4,5-tetrahydro-1h- benzoädüazepine als 5-ht2c-rezeptoragonisten
EP2001852A2 (en) 2006-04-03 2008-12-17 Arena Pharmaceuticals, Inc. Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto
CN101547892B (zh) * 2006-12-05 2014-08-20 艾尼纳制药公司 制备(r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓的方法和其中间体
US20100048632A1 (en) 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine GPCR Agonists
WO2009051747A1 (en) * 2007-10-15 2009-04-23 Concert Pharmaceuticals, Inc. Deuterated lorcaserin
EP2288585A1 (en) 2008-03-04 2011-03-02 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
AU2009231906A1 (en) 2008-03-31 2009-10-08 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
CA2727174A1 (en) 2008-06-20 2010-01-21 Jiangao Song Aryl gpr119 agonists and uses thereof
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
AU2010264720A1 (en) 2009-06-24 2011-12-08 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto

Also Published As

Publication number Publication date
MX2013002430A (es) 2013-07-22
AU2011296027A1 (en) 2013-04-04
EP2611781A1 (en) 2013-07-10
SG188363A1 (en) 2013-04-30
CN103189358A (zh) 2013-07-03
JP2013536858A (ja) 2013-09-26
IN2013DN02552A (https=) 2015-08-07
KR20130138768A (ko) 2013-12-19
US20140148442A1 (en) 2014-05-29
CA2808900A1 (en) 2012-03-08
WO2012030951A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
SG10201506873WA (en) Fast-dissolve dosage forms of 5-ht2c agonists
HUS2000018I1 (hu) Mellékvese hormon-módosító szer alkalmazása
IL224829B (en) Modified-release dosage forms of 5-ht2c agonists useful for weight management
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
EP2763994A4 (en) NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
IL224322A0 (en) Agonists of gpr40
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
EP2576552A4 (en) BENZOQUINOLONE INHIBITORS OF VMAT2
SI2526090T1 (sl) Nova sredstva proti malariji
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
ZA201206456B (en) Uses of dgati inhibitors
TWM389827U (en) Improved structure of lamp
PL2753330T3 (pl) Terapeutyczne zastosowania ektoiny
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
EP2536688A4 (en) STABLE DOSAGE FORMS OF LEVOMILNACIPRAN
PL2363354T3 (pl) Dozownik substancji czynnej
HK1187039A (en) Fast-dissolve dosage forms of 5-ht2c agonists
GB201004479D0 (en) Therapeutic use of new compounds I
HU1000688D0 (en) Use of trifluoro-phal
GB201004480D0 (en) Therapeutic use of new compounds II
GB201009614D0 (en) Therapeutic use of compounds
GB201019938D0 (en) Determination of therapeutic agents
GB0908609D0 (en) New use of isoQC inhibitors
GB201104632D0 (en) Use of medicament
PT2595952T (pt) Agonistas de gpr40